These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 22664014)

  • 1. Routine induction therapy in living donor liver transplantation prevents rejection but may promote recurrence of hepatitis C.
    Ghanekar A; Kashfi A; Cattral M; Selzner N; McGilvray I; Selzner M; Renner E; Lilly L; Levy G; Grant D; Greig P
    Transplant Proc; 2012 Jun; 44(5):1351-6. PubMed ID: 22664014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose RATG with or without basiliximab in renal transplantation: a matched-cohort observational study.
    Gentile G; Somma C; Gennarini A; Mastroluca D; Rota G; Lacanna F; Locatelli B; Remuzzi G; Ruggenenti P
    Am J Nephrol; 2015; 41(1):16-27. PubMed ID: 25612603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation.
    Flaman F; Zieroth S; Rao V; Ross H; Delgado DH
    J Heart Lung Transplant; 2006 Nov; 25(11):1358-62. PubMed ID: 17097501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose rabbit antithymocyte globulin versus basiliximab induction therapy in low-risk renal transplant recipients: 8-year follow-up.
    Laftavi MR; Alnimri M; Weber-Shrikant E; Kohli R; Said M; Patel S; Pankewycz O
    Transplant Proc; 2011 Mar; 43(2):458-61. PubMed ID: 21440733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction therapy by anti-thymocyte globulin (rabbit) versus basiliximab in deceased donor renal transplants and the effect on delayed graft function and outcomes.
    Foster CE; Weng RR; Piper M; Laugenou K; Ichii H; Lakey J; Malinoski D
    Transplant Proc; 2012 Jan; 44(1):164-6. PubMed ID: 22310605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
    Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D;
    N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10-10 Study participants.
    Lentine KL; Schnitzler MA; Xiao H; Brennan DC
    Trials; 2015 Aug; 16():365. PubMed ID: 26285695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection.
    Deeks ED; Keating GM
    Drugs; 2009 Jul; 69(11):1483-512. PubMed ID: 19634926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial.
    Carrier M; Leblanc MH; Perrault LP; White M; Doyle D; Beaudoin D; Guertin MC
    J Heart Lung Transplant; 2007 Mar; 26(3):258-63. PubMed ID: 17346628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promising early results with immunosuppression using rabbit anti-thymocyte globulin and steroids with delayed introduction of tacrolimus in adult liver transplant recipients.
    Tector AJ; Fridell JA; Mangus RS; Shah A; Milgrom M; Kwo P; Chalasani N; Yoo H; Rouch D; Liangpunsakul S; Herring S; Lumeng L
    Liver Transpl; 2004 Mar; 10(3):404-7. PubMed ID: 15004768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superior Patient and Graft Survival in Adult Liver Transplant with Rabbit Antithymocyte Globulin Induction: Experience with 595 Patients.
    Montenovo MI; Jalikis FG; Li M; Yeh M; Dick A; Hansen R; Reyes JD
    Exp Clin Transplant; 2017 Aug; 15(4):425-431. PubMed ID: 27309029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation.
    Pilch NA; Taber DJ; Moussa O; Thomas B; Denmark S; Meadows HB; McGillicuddy JW; Srinivas TR; Baliga PK; Chavin KD
    Ann Surg; 2014 May; 259(5):888-93. PubMed ID: 24513787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canadian national retrospective chart review comparing the long term effect of cyclosporine vs. tacrolimus on clinical outcomes in patients with post-liver transplantation hepatitis C virus infection.
    Yoshida EM; Lilly LB; Marotta PJ; Mason AL; Bilodeau M; Vaillancourt M
    Ann Hepatol; 2013; 12(2):282-93. PubMed ID: 23396740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basiliximab versus rabbit antithymocyte globulin as induction therapy for living-related renal transplantation: a single-center experience.
    Huang HF; Zhou JY; Xie WQ; Wu JY; Deng H; Chen JH
    Int Urol Nephrol; 2016 Aug; 48(8):1363-1370. PubMed ID: 27170340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction therapy with either anti-CD25 monoclonal antibodies or rabbit antithymocyte globulins in liver transplantation for hepatitis C.
    Kamar N; Borde JS; Sandres-Saune K; Suc B; Barange K; Cointault O; Lavayssière L; Durand D; Izopet J; Rostaing L
    Clin Transplant; 2005 Feb; 19(1):83-9. PubMed ID: 15659139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of immunosuppression induction with basiliximab compared to antithymocyte-globulin in adult heart transplant patients.
    Eberhardt TE; Kim DH; Nethersole S; Pearson GJ
    Clin Transplant; 2024 Jun; 38(6):e15332. PubMed ID: 38804609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of thymoglobulin and basiliximab in kidney transplant patients at high risk for acute rejection and delayed graft function.
    Chen G; Gu J; Qiu J; Wang C; Fei J; Deng S; Li J; Huang G; Fu Q; Chen L
    Exp Clin Transplant; 2013 Aug; 11(4):310-4. PubMed ID: 23121641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal.
    Martin ST; Roberts KL; Malek SK; Tullius SG; Vadivel N; De Serres S; Grafals M; Elsanjak A; Filkins BA; Chandraker A; Gabardi S
    Pharmacotherapy; 2011 Jun; 31(6):566-73. PubMed ID: 21923440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Antithymocyte Globulin, Basiliximab, and Induction-Free Treatment in Living Donor Kidney Transplant Recipients on Tacrolimus-Based Immunosuppression.
    Sonmez O; Ozcan SG; Karaca C; Atli Z; Dincer MT; Trabulus S; Seyahi N
    Exp Clin Transplant; 2024 Apr; 22(4):270-276. PubMed ID: 38742317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alemtuzumab induction in renal transplantation.
    Hanaway MJ; Woodle ES; Mulgaonkar S; Peddi VR; Kaufman DB; First MR; Croy R; Holman J;
    N Engl J Med; 2011 May; 364(20):1909-19. PubMed ID: 21591943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.